Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial.

Lester JF, Casbard AC, Al-Taei S, Harrop R, Katona L, Attanoos RL, Tabi Z, Griffiths GO.

Oncoimmunology. 2018 Sep 7;7(12):e1457597. doi: 10.1080/2162402X.2018.1457597. eCollection 2018.

PMID:
30524880
2.

Meet the researchers: an alternative method of engaging patients with research in mesothelioma.

Hill K, Portman M, Tabi Z.

Res Involv Engagem. 2018 Oct 15;4:33. doi: 10.1186/s40900-018-0119-x. eCollection 2018.

3.

Rab35-dependent extracellular nanovesicles are required for induction of tumour supporting stroma.

Yeung V, Webber JP, Dunlop EA, Morgan H, Hutton J, Gurney M, Jones E, Falcon-Perez J, Tabi Z, Errington R, Clayton A.

Nanoscale. 2018 May 10;10(18):8547-8559. doi: 10.1039/c8nr02417k.

PMID:
29693684
4.

Cancer stem cells as targets for immunotherapy.

Codd AS, Kanaseki T, Torigo T, Tabi Z.

Immunology. 2018 Mar;153(3):304-314. doi: 10.1111/imm.12866. Epub 2017 Dec 18. Review.

5.

Dominant immunosuppression of dendritic cell function by prostate-cancer-derived exosomes.

Salimu J, Webber J, Gurney M, Al-Taei S, Clayton A, Tabi Z.

J Extracell Vesicles. 2017 Sep 3;6(1):1368823. doi: 10.1080/20013078.2017.1368823. eCollection 2017.

6.

Prostaglandin E2-mediated adenosinergic effects on CD14+ cells: Self-amplifying immunosuppression in cancer.

Al-Taei S, Salimu J, Spary LK, Clayton A, Lester JF, Tabi Z.

Oncoimmunology. 2016 Dec 8;6(2):e1268308. doi: 10.1080/2162402X.2016.1268308. eCollection 2017.

7.

Cross-talk between cancer-initiating cells and immune cells: considerations for combination therapies.

Codd AS, Al-Taei S, Tabi Z.

Ann Transl Med. 2016 Oct;4(Suppl 1):S56. No abstract available.

8.

Proteomics analysis of vesicles isolated from plasma and urine of prostate cancer patients using a multiplex, aptamer-based protein array.

Welton JL, Brennan P, Gurney M, Webber JP, Spary LK, Carton DG, Falcón-Pérez JM, Walton SP, Mason MD, Tabi Z, Clayton A.

J Extracell Vesicles. 2016 Jun 29;5:31209. doi: 10.3402/jev.v5.31209. eCollection 2016.

9.

Prostate stromal cell proteomics analysis discriminates normal from tumour reactive stromal phenotypes.

Webber JP, Spary LK, Mason MD, Tabi Z, Brewis IA, Clayton A.

Oncotarget. 2016 Apr 12;7(15):20124-39. doi: 10.18632/oncotarget.7716.

10.

HOX transcription factors are potential targets and markers in malignant mesothelioma.

Morgan R, Simpson G, Gray S, Gillett C, Tabi Z, Spicer J, Harrington KJ, Pandha HS.

BMC Cancer. 2016 Feb 11;16:85. doi: 10.1186/s12885-016-2106-7.

11.

Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+ PD-L1+ phenotype in prostate cancer.

Spary LK, Salimu J, Webber JP, Clayton A, Mason MD, Tabi Z.

Oncoimmunology. 2014 Dec 13;3(9):e955331. eCollection 2014 Oct.

12.

Cross-Presentation of the Oncofetal Tumor Antigen 5T4 from Irradiated Prostate Cancer Cells--A Key Role for Heat-Shock Protein 70 and Receptor CD91.

Salimu J, Spary LK, Al-Taei S, Clayton A, Mason MD, Staffurth J, Tabi Z.

Cancer Immunol Res. 2015 Jun;3(6):678-88. doi: 10.1158/2326-6066.CIR-14-0079. Epub 2015 Feb 12.

13.

Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts.

Chowdhury R, Webber JP, Gurney M, Mason MD, Tabi Z, Clayton A.

Oncotarget. 2015 Jan 20;6(2):715-31.

14.

The boron efflux transporter ROTTEN EAR is required for maize inflorescence development and fertility.

Chatterjee M, Tabi Z, Galli M, Malcomber S, Buck A, Muszynski M, Gallavotti A.

Plant Cell. 2014 Jul;26(7):2962-77. doi: 10.1105/tpc.114.125963. Epub 2014 Jul 17.

15.

Enhancement of T cell responses as a result of synergy between lower doses of radiation and T cell stimulation.

Spary LK, Al-Taei S, Salimu J, Cook AD, Ager A, Watson HA, Clayton A, Staffurth J, Mason MD, Tabi Z.

J Immunol. 2014 Apr 1;192(7):3101-10. doi: 10.4049/jimmunol.1302736. Epub 2014 Mar 5.

16.

Proteomics analysis of cancer exosomes using a novel modified aptamer-based array (SOMAscan™) platform.

Webber J, Stone TC, Katilius E, Smith BC, Gordon B, Mason MD, Tabi Z, Brewis IA, Clayton A.

Mol Cell Proteomics. 2014 Apr;13(4):1050-64. doi: 10.1074/mcp.M113.032136. Epub 2014 Feb 6.

17.

Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes.

Webber JP, Spary LK, Sanders AJ, Chowdhury R, Jiang WG, Steadman R, Wymant J, Jones AT, Kynaston H, Mason MD, Tabi Z, Clayton A.

Oncogene. 2015 Jan 15;34(3):290-302. doi: 10.1038/onc.2013.560. Epub 2014 Jan 20.

PMID:
24441045
18.

Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy.

Al-Taei S, Banner R, Powell N, Evans M, Palaniappan N, Tabi Z, Man S.

Cancer Immunol Immunother. 2013 Dec;62(12):1821-30. doi: 10.1007/s00262-013-1488-5. Epub 2013 Oct 22.

PMID:
24146146
19.

Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma.

Al-Taei S, Salimu J, Lester JF, Linnane S, Goonewardena M, Harrop R, Mason MD, Tabi Z.

Lung Cancer. 2012 Aug;77(2):312-8. doi: 10.1016/j.lungcan.2012.03.008. Epub 2012 Apr 10.

PMID:
22498111
20.

Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production.

Clayton A, Al-Taei S, Webber J, Mason MD, Tabi Z.

J Immunol. 2011 Jul 15;187(2):676-83. doi: 10.4049/jimmunol.1003884. Epub 2011 Jun 15.

21.

Cancer exosomes trigger fibroblast to myofibroblast differentiation.

Webber J, Steadman R, Mason MD, Tabi Z, Clayton A.

Cancer Res. 2010 Dec 1;70(23):9621-30. doi: 10.1158/0008-5472.CAN-10-1722. Epub 2010 Nov 23.

22.

Resistance of CD45RA- T cells to apoptosis and functional impairment, and activation of tumor-antigen specific T cells during radiation therapy of prostate cancer.

Tabi Z, Spary LK, Coleman S, Clayton A, Mason MD, Staffurth J.

J Immunol. 2010 Jul 15;185(2):1330-9. doi: 10.4049/jimmunol.1000488. Epub 2010 Jun 14.

23.

IL-12 and type I IFN response of neonatal myeloid DC to human CMV infection.

Renneson J, Dutta B, Goriely S, Danis B, Lecomte S, Laes JF, Tabi Z, Goldman M, Marchant A.

Eur J Immunol. 2009 Oct;39(10):2789-99. doi: 10.1002/eji.200939414.

24.

Can urinary exosomes act as treatment response markers in prostate cancer?

Mitchell PJ, Welton J, Staffurth J, Court J, Mason MD, Tabi Z, Clayton A.

J Transl Med. 2009 Jan 12;7:4. doi: 10.1186/1479-5876-7-4.

25.

A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro.

Navabi H, Jasani B, Reece A, Clayton A, Tabi Z, Donninger C, Mason M, Adams M.

Vaccine. 2009 Jan 1;27(1):107-15. doi: 10.1016/j.vaccine.2008.10.024. Epub 2008 Oct 31.

PMID:
18977262
26.

SV40 large T antigen-specific human T cell memory responses.

Coleman S, Gibbs A, Butchart E, Mason MD, Jasani B, Tabi Z.

J Med Virol. 2008 Aug;80(8):1497-504. doi: 10.1002/jmv.21216.

PMID:
18551603
27.

Human tumor-derived exosomes down-modulate NKG2D expression.

Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z.

J Immunol. 2008 Jun 1;180(11):7249-58.

28.

Increased exosome production from tumour cell cultures using the Integra CELLine Culture System.

Mitchell JP, Court J, Mason MD, Tabi Z, Clayton A.

J Immunol Methods. 2008 Jun 1;335(1-2):98-105. doi: 10.1016/j.jim.2008.03.001. Epub 2008 Apr 3.

PMID:
18423480
29.

Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2.

Clayton A, Mitchell JP, Court J, Mason MD, Tabi Z.

Cancer Res. 2007 Aug 1;67(15):7458-66.

30.

Human cancer vaccines.

Man S, Tabi Z.

Adv Drug Deliv Rev. 2006 Oct 1;58(8):899-901. Epub 2006 Aug 17. No abstract available.

PMID:
17007959
31.

Challenges for cancer vaccine development.

Tabi Z, Man S.

Adv Drug Deliv Rev. 2006 Oct 1;58(8):902-15. Epub 2006 Aug 7. Review.

PMID:
16979786
32.

Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer.

Coleman S, Clayton A, Mason MD, Jasani B, Adams M, Tabi Z.

Cancer Res. 2005 Aug 1;65(15):7000-6.

33.

Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial.

Navabi H, Croston D, Hobot J, Clayton A, Zitvogel L, Jasani B, Bailey-Wood R, Wilson K, Tabi Z, Mason MD, Adams M.

Blood Cells Mol Dis. 2005 Sep-Oct;35(2):149-52.

PMID:
16061407
34.

Induction of heat shock proteins in B-cell exosomes.

Clayton A, Turkes A, Navabi H, Mason MD, Tabi Z.

J Cell Sci. 2005 Aug 15;118(Pt 16):3631-8. Epub 2005 Jul 26.

35.

Exosomes and the MICA-NKG2D system in cancer.

Clayton A, Tabi Z.

Blood Cells Mol Dis. 2005 May-Jun;34(3):206-13.

PMID:
15885603
36.

Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma.

Jasani B, Coleman S, Butchart E, Evans EM, Adams M, Mason M, Gibbs A, Tabi Z.

Vaccine. 2005 Mar 18;23(17-18):2399-402.

PMID:
15755635
37.

The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer.

Adams M, Navabi H, Croston D, Coleman S, Tabi Z, Clayton A, Jasani B, Mason MD.

Vaccine. 2005 Mar 18;23(17-18):2374-8.

PMID:
15755631
39.

Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells.

Moutaftsi M, Mehl AM, Borysiewicz LK, Tabi Z.

Blood. 2002 Apr 15;99(8):2913-21.

46.

Lack of cross-species sensitization between skin allo- and xenotransplants in mice.

Vizler C, Jánossy T, Tabi Z, Végh P.

Transplant Proc. 1994 Jun;26(3):1324-5. No abstract available.

PMID:
8029925
47.

Cellular events in the lymph node and lung of mice with influenza. Consequences of depleting CD4+ T cells.

Allan W, Tabi Z, Cleary A, Doherty PC.

J Immunol. 1990 May 15;144(10):3980-6.

PMID:
1692070
48.

Virus-specific memory T cells are Pgp-1+ and can be selectively activated with phorbol ester and calcium ionophore.

Tabi Z, Lynch F, Ceredig R, Allan JE, Doherty PC.

Cell Immunol. 1988 May;113(2):268-77.

PMID:
3282677
50.

Phenotypic analysis of the inflammatory exudate in murine lymphocytic choriomeningitis.

Ceredig R, Allan JE, Tabi Z, Lynch F, Doherty PC.

J Exp Med. 1987 Jun 1;165(6):1539-51.

Supplemental Content

Support Center